274 results on '"Lewis, Basil S."'
Search Results
2. SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from AHA
3. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA
4. GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity
5. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
6. Pericardial Late Gadolinium Enhancement and Time to Recurrence: A Substudy from RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Recurrent Pericarditis
7. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
8. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events
9. Abstract 47: Tapering And Discontinuation Of Background Therapies During The Transition To Rilonacept Monotherapy In Rhapsody, A Phase 3 Clinical Trial Of Rilonacept In Patients With Recurrent Pericarditis
10. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
11. Are SGLT2 inhibitors effective against ‘all’ heart failure with preserved ejection fraction?
12. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
13. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
14. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy
15. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy
16. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study
17. Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST
18. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
19. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
20. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
21. Guía ESC 2020 para el tratamiento de las cardiopatías congénitas del adulto
22. CARDIAC MAGNETIC RESONANCE IMAGING FOR GUIDING DECISION-MAKING ON TREATMENT DURATION: DATA FROM RHAPSODY, A PHASE 3 CLINICAL TRIAL OF RILONACEPT IN RECURRENT PERICARDITIS
23. TAPERING AND DISCONTINUATION OF BACKGROUND THERAPIES DURING THE TRANSITION TO RILONACEPT MONOTHERAPY IN RHAPSODY, A PHASE 3 CLINICAL TRIAL OF RILONACEPT IN PATIENTS WITH RECURRENT PERICARDITIS
24. Atrial fibrillation and stroke prevention
25. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
26. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis
27. Relation between Baseline Coronary Atherosclerotic Status, Cardiovascular Events, and Malignancies in Type 2 Diabetics: A Long-Term Prospective Cohort Study
28. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58
29. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
30. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
31. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials
32. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing
33. Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation
34. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction
35. MSc in clinical trials: a new flagship Working Group project
36. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction
37. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease
38. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
39. PCSK9 INHIBITION AND AORTIC STENOSIS IN THE FOURIER TRIAL
40. Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]
41. Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]
42. Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction
43. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
44. Use of Calcium Antagonists After Myocardial Infarction: Focus on the DEFIANT Studies
45. Ventricular Remodeling: From Bedside to Molecule
46. Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1
47. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
48. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
49. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials
50. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.